Released Nov 8, 2022, after the close
10-Q filed Nov 8, 2022, 39 days after period end · 0000950170-22-023233
Q3 2022 · 10-Q
Revenue—
Net Income-$23.15M-$23.15M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.48-$0.48 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$23,401,000N/M
Operating Cash Flowderived-$19,822,000N/M
Free Cash Flowderived-$19,924,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | — | $6.25M | $34.61M | $4.23M |
| Net Income | -$23.15M | -$18.80M | -$3.35M | -$25.00M |
| EPS Diluted | -$0.48 | -$0.41 | -$0.09 | -$0.96 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR